Bio-equivalence of Rosuvastatin 10 mg

2023-509661-21-00 Human pharmacology (Phase I) - Bioequivalence study Ongoing, recruiting

Start 3 Oct 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ongoing, recruiting
Participants planned 12
Countries 1
Sites 1

Healthy volunteers

Key facts

Sponsor
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
3 Oct 2024 → ongoing
Decision date (initial)
2024-08-21
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Sponsor organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Address
Dr. Molewaterplein 40
City
Rotterdam
Postcode
3015 GD
Country
Netherlands

Scientific contact point

Organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Contact name
Ruben Mijnster

Public contact point

Organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Contact name
Ruben Mijnster

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 12 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Internal Medicine, P. O. Box 2040, 3000 CA, Rotterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-10-03 2024-10-03

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-10 Netherlands Acceptable
2024-08-21
2024-08-21
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-19 Netherlands Acceptable
2024-10-03
2024-10-03
3 SUBSTANTIAL MODIFICATION SM-2 2025-02-06 Netherlands Acceptable
2025-02-17
2025-02-19
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-19 Netherlands 2025-02-19
5 SUBSTANTIAL MODIFICATION SM-3 2026-01-19 Netherlands Acceptable
2026-02-04
2026-02-04